Methods

Cremaster Muscle Preparation
This investigation abided by the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) . Sprague-Dawley rats weighing between 100 and 130 g were anesthetized with urethane (1.2 g/kg ip). The cremaster muscles were prepared for intravital microscopy following methods described in previous studies. 17 In brief, surgical exposure of the cremaster muscle began with an incision from the anterior iliac spine to the tip of the scrotum, exposing the inguinal ligament (the most caudal part of the anterior abdominal wall), and the cremaster muscle. The cremaster muscle was then incised along its least vascular sector, and the testicles were removed. With the aid of a stereomicroscope, the cremaster muscle was dissected out as a miniature island flap, attached to the body only by a neurovascular pedicle (pubic-epigastric artery and vein, and genitofemoral nerve). In the I/R group, to start the 4 h of ischemia, a single microvascular clamp was placed on the pubic epigastric artery, and 2 h of reperfusion was achieved by releasing the clamp. The sham-operated control animals underwent all surgical procedures without artery clamping. Before and during the ischemia or reperfusion period, heart rate (HR) and blood pressure (BP) were recorded. The animals were injected with the PKC inhibitor (chelerythrine, 5 mg/kg, iv), specific nNOS inhibitor (7-nitroindazole, 50 mg/kg, ip), iNOS inhibitor (S-methylisothiourea sulphate, 3 mg/kg, ip), or nonselective NOS inhibitor (N Gnitro-L-arginine methylester (L-NAME), 1 mg/kg, iv) 10 min before IPC to examine the effects.
Intravital Microscopy
The cremasteric microcirculation was visualized using an intravital microscope (Nikon Measurescope MM-22, Tokyo, Japan) with a ×40 objective lens (M plan 40/0.40 SLWD, Nikon, Japan) and a ×10 eyepiece. A color video camera (Sony DXC-750 MD, Tokyo, Japan) was used to project the images onto a calibrated monitor (Sony) and the images were recorded for analysis using a videocassette recorder (Sony SVO-9600, Tokyo, Japan). To minimize variability, 4-6 venules (25-40 m in diameter) were selected in each trial and the same section of each venule was observed throughout the experiment. The venular diameter and the number of rolling or adherent leukocytes were determined during off-line analysis. Rolling leukocytes were identified as cells moving at a slower velocity than that of the erythrocytes within a given vessel and the cell's velocity was determined by measuring the time required for a leukocyte to roll along a 100 m length of venule. Leukocyte rolling flux was defined as the number of rolling cells moving past a fixed point on the venular wall per minute and rolling flux was averaged over 2 min. Leukocytes were considered to be adherent to the venular endothelium if they remained stationary for 30 s or longer within a given 100 m vessel segment. Leukocyte migration was defined as the number of extravascular leukocytes visible per microscopic (×40) video field centered on a postcapillary venule, and was determined by averaging the data derived from 4-6 fields after I/R. Functional capillary density (flowing capillary density) was measured in 3 separate regions of the cremaster flap (proximal, middle, and distal) by counting the number of capillaries (with blood flow) per high-power field. The mean capillary density was obtained by averaging the capillary densities from the 3 regions of each cremaster flap and used for statistical comparison between the different groups.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RT-PCR was used to detect the presence of nNOS (NOS 1), iNOS (NOS 2), and eNOS (NOS 3) mRNA in the cremaster muscle. RNA was extracted from tissues with RNeasy Maxi kits (Qiagen, Valencia, CA, USA). Following DNase digestion, 2 g of RNA was subjected to RT-PCR with Superscript™ III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA), using oligo-dT as primers. RT-PCR was carried out in O' in 1 DNA polymerase solution (Yeastern, Taiwan) at 52°C for 60 min followed by enzyme inactivation at 70°C for 15 min. The primer sequences are shown in Table 1 . A range of RT-PCR was performed (25, 30, 35 and 40 cycles) . The reactions that proceeded for 25-35 cycles were found to be within the logarithmic phase of amplification and yielded reproducible results. The amplification procedure consisted of initial denaturation (95°C for 5 min) followed by 25, 30, 35 or 40 cycles of denaturation (95°C for 1 min), annealing (nNOS 65°C, iNOS 57°C, and eNOS 60°C for 1 min), and extension (72°C for 1 min). The amplified products were separated via gel electrophoresis in 1.5% agarose gel containing 0.5 mg/ml ethidium bromide.
Statistics
Differences in functional capillary density and leukocyte count were analyzed statistically. One-way analysis of variance was used to determine the variables that were likely to show the differences between the sham-operated control, the I/R, IPC + I/R and chelerythrine + IPC + I/R groups. These variables were subsequently analyzed for significant differences between the groups with Student's t-test. Statistical significance was at p<0.05 and all tests were 2-tailed.
Results
Leukocyte Rolling, Adhesion, and Transmigration
Low rates of leukocyte rolling, adhering and transmigrating leukocytes were observed in the postcapillary venules of the cremaster muscle (Fig 1, p<0.05) . In contrast, reductions in I/R-induced leukocyte rolling, adhering and transmigrating occurred in the animals primed with short-term IPC (30 min ischemia followed by 30 min reperfusion) (Fig 1, IPC + I/R group vs I/R group, p<0.05). However, these anti-leukocyte effects of IPC were antagonized by chelerythrine (5 mg/kg) (Fig 1) .
Functional Capillary Density
From the sham-operated control group (baseline), the number of functional capillaries varied 11.42±0.44 per 9 fields of view among the experimental animals. IPC treatment alone did not diminish the baseline level of capillary perfusion. After 4 h of ischemia followed by 2 h of reperfusion, the I/R-injured rat cremaster muscle showed a marked reduction in the number of functional capillaries compared with the sham-operated control animals (p<0.05). In contrast, more functional capillaries were observed in the animals primed with short-term IPC prior to I/R. The number of functional capillaries in the IPC + I/R group was 19.52% more than that of the I/R group (Fig 2) . Finally, pretreatment with chelerythrine antagonized the IPC protective effect on the recovery of functional capillary perfusion. Furthermore, there was no significant difference in HR or BP among the experiment groups.
NOS mRNA Expression in I/R Injured Cremaster Muscle
There was no statistically significant difference between the sham-operated control cremaster muscle and the IPC treated cremaster muscle in the nNOS, iNOS, and eNOS gene expressions (Fig 3) . On the other hand, the I/R group showed decreased nNOS and eNOS mRNA expressions of 36% (p<0.05) and 33% (p<0.05), respectively, compared with the sham-operated control group (Fig 3) . The I/R group did not show any significant change in iNOS mRNA expression. In the IPC + I/R group, the mRNA expression of the 3 isoforms was upregulated by 240%, 366%, and 237%, respectively, compared wityh the I/R group (p<0.05, Fig 3) . These results suggest that nNOS, iNOS, and eNOS mRNA were upregulated in the I/R injured cremaster muscle primed with IPC. Furthermore, our results also showed that PKC inhibitor (chelerythrine) did not antagonize the effects of IPC in the upregulations of nNOS, iNOS, and nNOS mRNA expressions (Fig 3) .
Effect of NOS Inhibitors on IPC-Ameliorated IR/-Induced Leukocyte -Endothelial Cell Interaction
Three NOS inhibitors (specific nNOS inhibitor, 7-nitroindazole, 50 mg/kg ip; specific iNOS inhibitor, S-methylisothiourea sulphate, 3 mg/kg ip; and nonselective NOS inhibitor, L-NAME, 1 mg/kg iv) were used to show the antagonistic effects of IPC prevention of I/R-induced leukocyte -endothelium interactions. Inhibition of both nNOS and iNOS activity did not antagonize the anti-leukocyte effect of IPC (Fig 4) , whereas administration of the nonselective NOS inhibitor (L-NAME) prior to IPC almost completely blocked the protective effect of IPC (Fig 4) . L-NAME also has an antioxidant property, so D-NAME was used as a control to demonstrate the true "anti-NOS" effects of L-NAME ( Fig 5) .
Discussion
IPC is an endogenous protective phenomenon that makes muscle more tolerant to subsequent prolonged ischemia. 18 Since its discovery in 1986, 3 IPC has attracted considerable interest for 2 reasons. First, preconditioning is the most powerful tool presently known to reduce post-ischemic injury, 19 and second, the growing number of patients requiring transplantations has increased the clinical relevance of IPC. Knowledge of the underlying mechanisms of precondition- ing may help in designing pharmacological interventions to keep tissues in a "permanent state of preconditioning" and thereby protecting them from injury. 19 Numerous attempts have been made to elucidate the mechanisms behind preconditioning, but results have suggested nearly as many possible mediators as there have been attempts. These possible mediators include NO, 20 acetylcholine, 21 catecholamines, 22 angiotensin II, 23 bradykinin, 24 adenosine, 25 and reactive oxygen species (ROS). 26, 27 Although the roles of NOS/NO and PKC in IPC in the heart and many other organs have been extensively discussed, [28] [29] [30] only few studies have investigated skeletal muscle [31] [32] [33] and the microcirculatory leukocyte-endothelium interaction. The current literature suggests that a brief period of I/R rapidly generates vasoactive mediators, such as adenosine, that may serve as initiators of a complex signal transduction cascade, which may involve PKC. Because PKC can be activated by either IPC or other extracellular stimuli such as catecholamine ( 1-adrenoceptor stimulation), 34 lipopolysaccharide and phorbol 12-myristate 13-acetate, leading to cardioprotection, it has come to be recognized as a major mediator of IPC. 35 Furthermore, experimental evidence suggests that PKC then leads to activation of transcription factors, upregulation of genes, and synthesis of effector proteins such as NOS. 36 NOS then produces NO, which has been reported to share downstream pathways with various other triggers (such as acetylcholine, bradykinin, opioids, and phenylephrine), involving PKC, KATP channels, and the generation of ROS in the triggering phase of IPC. 37 On the other hand, Dawn and Bolli reported that PKC activates nuclear factor-B after several hours leading to increased expression of iNOS, conferring resistance to subsequent ischemic stress. 36 Overall, there are still controversies regarding the roles of PKC and NOS/NO signaling in IPC for the amelioration of I/R-induced leukocyte -endothelium interactions and further investigation is needed to elucidate the mechanism.
In the present experiment, I/R markedly increased the number of rolling, adhering and transmigrating leukocytes in the postcapillary venules of rat cremaster muscle (Fig 1) , whereas priming with IPC prevented these I/R-induced increases. Moreover, in the chelerythrine + IPC + I/R group, IPC's protective effect was completely inhibited, so PKC appeared to have mediated the protection. It has been reported that IPC can rapidly stimulate NOS expression in skeletal muscle, 38 so we examined whether IPC can trigger protection via activation of the NOS -NO pathway. The results show that in the IPC + I/R group, all 3 isoforms of NOS were upregulated as compared with the I/R group (Fig 3) . However, this upregulation of the mRNA expression of the different isoforms of NOS was not affected by the PKC inhibitor (chelerythrine), which suggests that PKC did not mediate the anti-leukocyte -endothelium effect of IPC via a NO-dependent mechanism.
Recently, nNOS has been thought to be an important regulator of blood flow in contracting skeletal muscles, 39 where it may act via a cGMP-dependent cascade to relax vascular smooth muscles 40 or antagonize the reflex sympatheticadrenergic vasoconstriction. 41 It has also been suggested that I/R upregulates iNOS expression, and that inhibition of iNOS improves contractile function and blood flow. 42 However, other studies have shown that induction of iNOS, by prior administration of monophosphoryl lipid A, conferred myocardial protection against I/R injury. 43 It seems that a dichotomy of action for iNOS/NO exists, because manipulation of NO production has been shown to have both detrimental and beneficial effects in I/R hearts. 44 In addition, constitutively expressed eNOS produces low concentrations of NO, which is necessary for good endothelial function and integrity. Endothelial-derived NO is often seen as a protective agent in a variety of diseases, such as I/R injury. 45 The present results showed that in the I/R group, nNOS and eNOS mRNA expressions were decreased to 64% (p<0.05) and 67% (p<0.05), respectively, compared with the mRNA expressions in the sham-operated control group (Fig 3) .
In order to clarify which isoform of NOS was responsible for the IPC-attenuated leukocyte -endothelium interactions in I/R-induced microcirculatory disturbance, NOS inhibitors were used to examine their possible antagonistic effects. Our results show that in animals primed with IPC, nNOS, and iNOS mRNA expressions were upregulated in the I/R injured cremaster muscle. However, inhibition of nNOS and iNOS activities did not block the beneficial effects of IPC. In contrast, pretreatment with the nonselective NOS inhibitor (L-NAME) in the IPC + I/R group almost completely blocked the protective effect of IPC. The abolition of preconditioning by L-NAME (but not selective nNOS nor iNOS inhibition) suggests that NO produced by eNOS is a key mediator of IPC in attenuating I/R-induced leukocyte -endothelium interactions. Our results are consistent with the findings of Laude et al 46 and Muscari et al 47 who both suggested that NO produced by eNOS may play an important role in early and/or delayed preconditioning. However, there is still a possibility that NO derived from any 1 of 3 isoforms of NOS is sufficient to mediate the protective effect of IPC and that all 3 isoforms of NOS must be simultaneously inhibited to abrogate the protective effect of IPC, which may be consistent with the finding of upregulation of all 3 NOS during I/R + IPC (Fig 3) . Further investigation is needed to elucidate this discrepancy.
Conclusion
Both NOS and PKC are involved in the protective effect of IPC in the I/R-induced microcirculatory disturbance, but probably in distinct ways. Overall, the findings suggest that eNOS and PKC among the various mediators might be potentially associated with IPC.
